arrow
J

John P. Maxwell

tango therapeutics
H指数:13
被引数:769

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

MTA-Cooperative PRMT5 Inhibitors Demonstrate Efficacy in MTAP-Deleted MPNST Models and Enhance Chemotherapy Response

MTA协同的PRMT5抑制剂在MTAP缺失的MPNST模型中显示出疗效并增强化疗反应

2025-11-010
OAAI
Discovery of TNG-6132, a potent, selective, and orally bioavailable USP1 inhibitor

TNG-6132的发现,一种强效、选择性且口服生物利用度高的USP1抑制剂

2025-05-150
PRE
Discovery of TNG908: A Selective, Brain Penetrant, MTA-Cooperative PRMT5 Inhibitor That Is Synthetically Lethal with MTAP-Deleted Cancers
2024-04-1010
OAAI
TNG917 is a clinical-grade, potent and selective inhibitor of EHMT1/2 for the treatment of immune cold tumors
2024-03-220
PRE
Unbiased in vitro and in vivo drug anchor screens identify mechanisms of resistance and sensitization for MTA-cooperative PRMT5 inhibitors in MTAP-deleted cancer models
2023-12-010
PRE
TNG348, a selective USP1 inhibitor, shows strong preclinical combination activity with PARP inhibitors and other agents targeting DNA repair
2023-12-012
PRE
Characterization of the clinical development candidate TNG348 as a potent and selective inhibitor of USP1 for the treatment of BRCA1/2mut cancers
2023-04-042
PRE
Ubiquitinated PCNA Drives USP1 Synthetic Lethality in Cancer
2022-10-1231
OAAI